Curriculum: Personalised management of Prostate Cancer patients with history and risk of CVD events
This online curriculum addresses the unmet needs in personalised management of Prostate Cancer patients with history and risk of CVD events and is a mix of live webinars, case discussions, Q&A and discussions by key opinion leaders in prostate cancer. The programme is developed by The Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology.
The curriculum is divided in a series of educational online modules, each one consisting of pre-recorded sessions and a live webinar. Participants are recommended to watch the pre-recorded lectures as a preparation for the live webinar. Attending the live webinar is free (registration required) and participants joining live will receive accreditation points.
On Demand
Webinar series: Principles of Optimal Multidisciplinary Management in Clinical Practice
Webinar 4: Ongoing Clinical Research in Prostate Cancer: What can we anticipate?
Date: Monday, November14 – 6:00 PM
Moderators:
Diogo Bastos, MD
Anthony Ng, MD
This session will cover the future of prostate cancer survivorship research:
What’s next in Prostate Cancer research? – Alberto Briganti, MD
What lessons for prostate cancer can we learn about multidisciplinary treatment for breast cancer? – Susan Dent, MD
Enhancing CVD and prostate cancer survivorship-how is this best done? – Darryl Leong, MD
Discussion/question and answer, 15 minutes
Topics to cover in this session:
CV decision-making in advanced PC
Discuss factors that influence recommendations for CABG, valve surgery, transcatheter valve intervention in patients with metastatic PC
Optimal cardioprotective therapy for high-risk patients
Should ADT or androgen receptor blockers be withheld (if ever)?
Acute MI, HTN out of control, etc.
Any CV conditions that preclude this treatment
Considerations of complex decisions around antithrombotic therapies
Webinar 3: Collaborative Practice in Prostate Cancer: How is this actually done?
Date: Monday, September 12 – 6PM
Moderators:
Dr. Daniel Lenihan (US)
Assco. Prof. Andrew Armstrong (US)
Dr. Michiel Sedelaar (NL)
This session will involve the presentation of challenging cases highlighting issues encountered in actual clinical decision making.
Topics to cover in this session:
CV decision-making in advanced PC
Discuss factors that influence recommendations for CABG, valve surgery, transcatheter valve intervention in patients with metastatic PC
Optimal cardioprotective therapy for high-risk patients
Should ADT or androgen receptor blockers be withheld (if ever)?
Acute MI, HTN out of control, etc.
Any CV conditions that preclude this treatment
Considerations of complex decisions around antithrombotic therapies
Webinar 2: How have the recent clinical trials in Prostate Cancer informed my practice choices?
Faculty
Moderators: Dr. Juan Gómez Rivas (ES) and Prof. Katie Zhang (US)
Presenter: Dr. Ricardo Rendon (CA) – “Pivotal trials that have changed my practice”
Assco. Prof. Alicia Morgans (US) – “The role of different hormonal based therapies in Prostate Cancer”
Prof. Renato Lopes (US) – “Summarizing the CV toxicities for prostate cancer therapies (including the PRONOUNCE trial)”
Webinar 1: What clinical factors influence treatment decisions for localized prostate cancer?
Faculty
Moderators: Dr. Tia Higano (CA) and Prof. Derya Tilki (DE)
Presenter: Dr. Neil Fleshner (CA) – “Prostate Cancer: The Basics in 2022”
Dr. Paul L. Nguyen (US) – “The use of ADT with Radiation for Prostate Cancer”
Dr. Chris Plummer (UK) – “Which screening tests and initial treatments are needed to prevent CVD progression?”
Faculty: Moderator: Prof. P-A. Abrahamsson (SE); Presenters: Dr. Neil Fleshner (CUA), Dr. Marc Garnick (EAU), Dr. Daniel Lenihan (ICOS)
Module 3: Advances in safety in the treatment of PCa
Pre-recorded lectures
Dr. Alan So (CUA): Safety data – GNRH Analogues, focus on CVD risk profile
Prof. Axel Merseburger (EAU): Safety data – mHSPC therapy and CVD risk profile
Live webinar
Ass. Prof. Katie Zhang (ICOS): Live case study (incl Cardiac biomarkers) + Q&A by panellists Dr. Alan So & Prof. Axel Merseburger
Module 2: Debate – How to manage CVD risk in PCa patients during COVID 19
Live webinar
Faculty
Moderator: Prof. P-A. Abrahamsson (SE)
Presenter: Prof. A. Ghosh (GB) – “Impact of COVID-19 on cardio-oncology”
Dr. M. Linch (GB) – “Hormonal treatment of urological cancers during COVID-19”
Dr. R.A. Rendon (CA) – “How to manage prostate cancer in a pandemic”
Prof. Dr. M.J. Ribal Caparros (ES) – “COVID-19 Recommendations for Prostate Cancer treatment by the EAU Guidelines”
Module 1: CVD in prostate cancer patients – Increased risks & comorbidities
Pre-recorded lectures
Phil Cornford – EAU: The comorbidity burden in prostate cancer
Darryl Leong – ICOS: Risk scoring of CVD in PCa patients undergoing hormonal PCa treatment
Live webinar
Faculty: Laurence Klotz – CUA: Live Case discussion + Q&A by panellists Darryl Leong & Phil Cornford
Cardiovascular considerations in PCa patients treated with ADT
This educational activity has been funded by Ferring Pharmaceuticals. The educational programme of this online activity has been a collaboration with Ferring, but independently developed and approved by the Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology.
